HUE058914T2 - Gyógyszer elõállítására szolgáló eljárások és köztitermékek - Google Patents

Gyógyszer elõállítására szolgáló eljárások és köztitermékek

Info

Publication number
HUE058914T2
HUE058914T2 HUE14708885A HUE14708885A HUE058914T2 HU E058914 T2 HUE058914 T2 HU E058914T2 HU E14708885 A HUE14708885 A HU E14708885A HU E14708885 A HUE14708885 A HU E14708885A HU E058914 T2 HUE058914 T2 HU E058914T2
Authority
HU
Hungary
Prior art keywords
intermediates
medicament
preparing
processes
Prior art date
Application number
HUE14708885A
Other languages
English (en)
Inventor
Philip Pye
Haim Cyril Ben
Matteo Conza
Ioannis Nicolaos Houpis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUE058914T2 publication Critical patent/HUE058914T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HUE14708885A 2013-03-15 2014-03-11 Gyógyszer elõállítására szolgáló eljárások és köztitermékek HUE058914T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786842P 2013-03-15 2013-03-15
EP13159470 2013-03-15
EP13197813 2013-12-17

Publications (1)

Publication Number Publication Date
HUE058914T2 true HUE058914T2 (hu) 2022-09-28

Family

ID=51535892

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14708885A HUE058914T2 (hu) 2013-03-15 2014-03-11 Gyógyszer elõállítására szolgáló eljárások és köztitermékek

Country Status (19)

Country Link
EP (1) EP2970291B1 (hu)
JP (1) JP6777398B2 (hu)
KR (2) KR102377688B1 (hu)
CN (2) CN112608298A (hu)
AU (2) AU2014230935A1 (hu)
BR (1) BR112015021856A2 (hu)
CA (1) CA2901510C (hu)
DK (1) DK2970291T3 (hu)
EA (1) EA201591685A1 (hu)
ES (1) ES2924193T3 (hu)
HR (1) HRP20220628T1 (hu)
HU (1) HUE058914T2 (hu)
LT (1) LT2970291T (hu)
MX (2) MX2015012731A (hu)
MY (1) MY194905A (hu)
PE (1) PE20151652A1 (hu)
SG (2) SG10201809696UA (hu)
SI (1) SI2970291T1 (hu)
WO (1) WO2014139970A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3196202T (pt) 2011-09-02 2019-05-31 Incyte Holdings Corp Heterociclilaminas como inibidores de pi3k
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
CN104447761A (zh) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 一种吡唑衍生物的制备方法
CN105481862B (zh) * 2015-01-21 2018-08-21 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途
US10266535B2 (en) 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof
LT3831833T (lt) * 2015-02-27 2023-02-27 Incyte Holdings Corporation Pi3k inhibitoriaus gamybos būdai
LV15201B (lv) 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts Ibrutiniba izejvielas iegūšanas paņēmiens
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-(4-苯氧基)苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103058A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
CN109311883B (zh) * 2017-02-09 2021-03-19 合肥合源药业有限公司 Flt3激酶抑制剂或其盐的晶型及其制备方法
CN107383017B (zh) * 2017-07-20 2020-01-14 河南师范大学 依鲁替尼高效制备方法
WO2019027860A1 (en) * 2017-08-01 2019-02-07 Boehringer Ingelheim International Gmbh INTERMEDIATE COMPOUNDS AND METHODS
BR112021022347A2 (pt) 2019-05-21 2022-01-04 Janssen Pharmaceutica Nv Processos e intermediários para a preparação de um inibidor de btk
CA3135211A1 (en) * 2019-05-21 2020-11-26 Philip James Pye Processes and intermediates for preparing a btk inhibitor
CN113200987A (zh) * 2021-04-29 2021-08-03 湖南华腾制药有限公司 一种伊布替尼的制备方法
CN115322226B (zh) * 2022-08-17 2023-08-11 厦门大学 一种共价靶向砷抑制剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354249A1 (en) * 1999-09-17 2003-12-29 Abbott Gmbhabbott Gmbh Pyrazolopyrimidines as therapeutic agents
SI2530083T1 (sl) * 2006-09-22 2016-09-30 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
CA2668286C (en) * 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
AU2008232762B2 (en) * 2007-03-28 2013-09-19 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
KR20120003868A (ko) 2009-03-31 2012-01-11 베링거 인겔하임 인터내셔날 게엠베하 1―헤테로사이클릴―1,5―디하이드로―피라졸로[3,4―d]피리미딘―4―온 유도체 및 pde9a 조절인자로서의 이의 용도
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2590982B1 (en) * 2010-07-09 2017-08-23 The Walter and Eliza Hall Institute of Medical Research Protein kinase inhibitors and methods of treatment
WO2012058645A1 (en) * 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9376438B2 (en) * 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
MX2014000518A (es) * 2011-07-13 2014-05-30 Pharmacyclics Inc Inhibidores de la tirosina quinasa de bruton.
EP2882741B1 (en) * 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
AP2015008381A0 (en) * 2012-11-02 2015-04-30 Pfizer Bruton's tyrosine kinase inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
MY194905A (en) 2022-12-22
MX2015012731A (es) 2016-02-18
EP2970291A1 (en) 2016-01-20
AU2018204086B2 (en) 2020-03-12
KR20150132172A (ko) 2015-11-25
LT2970291T (lt) 2022-06-10
KR102377688B1 (ko) 2022-03-22
SI2970291T1 (sl) 2022-07-29
MX2020012596A (es) 2021-02-09
SG10201809696UA (en) 2018-11-29
CA2901510A1 (en) 2014-09-18
AU2014230935A1 (en) 2015-09-03
AU2018204086A1 (en) 2018-06-28
BR112015021856A2 (pt) 2017-07-18
PE20151652A1 (es) 2015-11-12
HRP20220628T1 (hr) 2022-06-24
KR102311329B1 (ko) 2021-10-14
JP6777398B2 (ja) 2020-10-28
CA2901510C (en) 2022-11-29
DK2970291T3 (da) 2022-08-01
WO2014139970A1 (en) 2014-09-18
SG11201507595XA (en) 2015-10-29
EA201591685A1 (ru) 2016-01-29
CN105026400A (zh) 2015-11-04
JP2016510779A (ja) 2016-04-11
CN112608298A (zh) 2021-04-06
KR20210123429A (ko) 2021-10-13
EP2970291B1 (en) 2022-05-11
ES2924193T3 (es) 2022-10-05

Similar Documents

Publication Publication Date Title
ZA201905426B (en) Drug combinations
SG11201507595XA (en) Processes and intermediates for preparing a medicament
IL245211A0 (en) an inhaler for the medicine
AU351520S (en) Inhaler
AU352076S (en) Inhaler
HUE038547T2 (hu) Inhalátor
GB2533747B (en) A patient interface
HUE064186T2 (hu) Inhalátor
HUE053417T2 (hu) Inhalátor
GB2530229B (en) A splint
SG11201602693QA (en) Methods and intermediates for preparing macrolactams
GB201313835D0 (en) A medicament
HRP20181933T1 (hr) Farmaceutski postupak i intermedijari
HK1216178A1 (zh) 用於製備藥物的方法和中間體
GB201320786D0 (en) Medicament
GB201311546D0 (en) A bandage
GB201305071D0 (en) A wheelchair
AU348321S (en) A wheelchair